Metastatic Solid Tumor Clinical Trials in Denver, Colorado

7 studies are recruiting for metastatic solid tumor in Denver, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Rocky Mountain Cancer Center, Denver, Colorado

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

   The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at HealthOne, Denver, Colorado

   Locations

   33 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06561685 on ClinicalTrials.gov

3. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at HealthOne, Denver, Colorado

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

4. A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

   Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or metastatic human epidermal growth factor receptor 2 (HER2) -altered non-sm…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at HealthONE, Denver, Colorado

   Locations

   21 in total

   Run by

   Nuvalent Inc.

   See if you can join NCT06521554 on ClinicalTrials.gov

5. JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

   This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at HealthONE, Denver, Colorado

   Locations

   10 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT06108050 on ClinicalTrials.gov

6. A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

   Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid …

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of Colorado Cancer Center, Denver, Colorado

   Locations

   63 in total

   Run by

   Nuvalent Inc.

   See if you can join NCT05118789 on ClinicalTrials.gov

7. ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

   ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, fir…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Denver Drug Development Unit, Denver, Colorado

   Locations

   9 in total

   Run by

   Acepodia Biotech, Inc.

   See if you can join NCT06415487 on ClinicalTrials.gov